Caribou Biosciences, Inc. (CRBU): Total Assets
$175.37M
As of 2025-12-31
$142.77M
As of 2026-06-30
-22.3%
3-year compound annual growth
+37.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $175.37M | -44.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $313.31M | -27.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $432.21M | +15.6% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $373.76M | -15.5% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $442.36M | n/m | 2023-03-09, Balance as of period end |
| 2020-12-31 | $36.05M | n/a | 2022-03-21, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $228.79M | -38.4% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $79.73M | +57.1% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $343.32M | +114.1% |
| Curis Inc (CRIS) | 2025-12-31 | $19.97M | -51.6% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $621.33M | -28.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
Compare CRBU, TCRX, ACOG, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗